New advanced therapy medicinal product for cartilage defect treatment with extemporaneous association of a scaffold and Wharton's jelly mesenchymal stromal cells - Université de Lorraine Access content directly
Conference Papers Year : 2017

New advanced therapy medicinal product for cartilage defect treatment with extemporaneous association of a scaffold and Wharton's jelly mesenchymal stromal cells

Abstract

n the framework of an ANR project obtained in 2015, we propose to develop a new advanced therapy medicinal product for cartilage defect treatment with extemporaneous association of a scaffold and Wharton’s jelly mesenchymal stromal cells (WJ-MSC). Due to their capacity of proliferation and differentiation, MSC appear to be currently one of the most promising ways of obtaining cartilage cells. The conjunctive tissue of the umbilical cord or Wharton’s jelly is an abundant and promising source of MSC for clinical applications. They present immunomodulatory properties and have a higher proliferation potential than MSC from adult tissues. All these advantages enable this source to represent a virtually inexhaustible source of stem cells especially for allogeneic tissue engineering therapies. The first part of this work made it possible to perform a technological transfer from research towards the clinic. The transfer consisted in adjusting MSC isolation, production and conservation methods developed by research lab in clinical grade conditions. Eight umbilical cords were obtained after the signing of an informed consent form by pregnant mothers. In parallel, for each umbilical cord collected, well identified obstetric factors were recorded. We developed a fast, simple and efficient explant method for the isolation of MSC from human umbilical cords requiring minimal manipulation and thus reducing the risk of contamination. MSC isolation, production and conservation were performed in a controlled atmosphere zone. All reagents and materials were well-defined and controlled. Cell culture was performed in culture containers (CellSTACK®, Macopharma) in a closed system. MSC were cultivated in hypoxia until passage 2 and then frozen. Quality controls were carried out during production: serological and microbiological controls, cell number, viability, clonogenic capacity, immunophenotype, mesodermic differentiation potential and karyotype. This isolation method showed a 100% success rate. We were able to obtain a large number of viable and secured cells with an average number of 50.106 cells per CellSTACK and a doubling time of about 1.5 days. During the culture, WJ-MSC exhibited a sustained clonogenic capacity and a specific mesenchymal phenotype. These results made it possible to assess the feasibility and to validate the clinical grade amplification technique as well as to obtain precisely characterized and secured WJ-MSC.
No file

Dates and versions

hal-03612827 , version 1 (25-03-2022)

Identifiers

  • HAL Id : hal-03612827 , version 1

Cite

Loïc Reppel, Céline Huselstein, Natalia de Isla, Nathalie Rouas-Freiss, Philippe Moreau, et al.. New advanced therapy medicinal product for cartilage defect treatment with extemporaneous association of a scaffold and Wharton's jelly mesenchymal stromal cells. 7th international symposium Europe-China Stem cells and Médecine Regenerative, Oct 2017, Shangrao, China. ⟨hal-03612827⟩
56 View
1 Download

Share

Gmail Facebook X LinkedIn More